A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose, Dose-escalation Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Volunteers
Latest Information Update: 15 Jun 2026
At a glance
- Drugs DWP 212525 (Primary)
- Indications COVID 2019 infections; Inflammatory bowel diseases
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daewon Pharmaceutical
Most Recent Events
- 08 Jun 2026 Planned number of patients changed from 76 to 84.
- 08 Jun 2026 Planned End Date changed from 30 Jun 2026 to 30 Mar 2027.
- 08 Jun 2026 Planned primary completion date changed from 30 Jun 2026 to 30 Dec 2026.